Wells Fargo Sticks to Its Buy Rating for Ryan Specialty Group (RYAN)
In a report released yesterday, Elyse Greenspan from Wells Fargo maintained a Buy rating on Ryan Specialty Group, with a price target of $61.00. The company’s shares closed yesterday at $56.88.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Greenspan covers the Financial sector, focusing on stocks such as Progressive, Ryan Specialty Group, and Arthur J Gallagher & Co. According to TipRanks, Greenspan has an average return of 6.2% and a 54.65% success rate on recommended stocks.
In addition to Wells Fargo, Ryan Specialty Group also received a Buy from Barclays’s Alex Scott in a report issued on November 19. However, on November 20, Piper Sandler initiated coverage with a Hold rating on Ryan Specialty Group (NYSE: RYAN).
Based on Ryan Specialty Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $754.58 million and a net profit of $31.09 million. In comparison, last year the company earned a revenue of $604.69 million and had a net profit of $17.59 million
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RYAN in relation to earlier this year. Most recently, in September 2025, Patrick G. Ryan, the EC of RYAN bought 276,634.00 shares for a total of $14,337,940.22.
Read More on RYAN:
Disclaimer & DisclosureReport an Issue
- Ryan Specialty price target lowered to $65 from $70 at Barclays
- Ryan Specialty initiated with a Neutral at Piper Sandler
- Ryan Specialty Group: Balancing Strengths and Challenges in a Competitive Niche
- Ryan Specialty price target raised to $67 from $65 at Morgan Stanley
- Ryan Specialty price target lowered to $66 from $70 at BMO Capital
